Creative Planning
ACAD icon

Creative Planning’s Acadia Pharmaceuticals ACAD Stock Holding History

Creative Planning’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,000
Closed -$18K – 3751
2014
Q1 		$18K Buy
+4,000
New +$101K ﹤0.01% 2432

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Creative Planning's ACAD Position: Q2 2026 in Review

Creative Planning reduced its Acadia Pharmaceuticals (ACAD) stake by 7.6% in Q2 2026, selling an estimated $79.7K and leaving 43,862 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2553.

Creative Planning first reported a position in ACAD in Q2 2013 and has held it in 47 quarters since. The position peaked at $2.18M in Q4 2017. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Creative Planning held 43,862 shares of Acadia Pharmaceuticals worth $1.11M as of Q2 2026.
  • Creative Planning sold 3,623 Acadia Pharmaceuticals shares in Q2 2026, an estimated $79.7K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2553 holding.
  • Creative Planning first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • Creative Planning's Acadia Pharmaceuticals position peaked at $2.18M in Q4 2017.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.